Wolfgang Miesbach: Factor VIII Aurora Redefines the Biology of Coagulation
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn about a recent article by Johnathan J. Morris et al, published in American Society of Hematology, adding:
“Haemophilia A is defined by too little factor VIII.
So what happens when FVIII works too well?
Factor VIII Aurora (FVIII-R571S) — newly characterised in Blood by Lindsey George and colleagues at CHOP — is the first naturally occurring gain-of-function FVIII variant. It was identified in a patient with recurrent thrombosis and early death (NEJM 2025), and the mechanism turns out to be strikingly simple:
A single amino acid change raises the affinity of activated FVIII for FIXa by 10–20-fold. That one property accounts for the entire phenotype:
- 6-fold higher one-stage activity, yet normal chromogenic activity — the CSA uses FIXa in excess and is blind to the difference
- ‘APC resistance’ that isn’t intrinsic: the variant is cleaved by APC normally, but tighter FIXa binding shields it
- reduced A2-domain dissociation
- 4–5-fold greater haemostatic potency and a clearly prothrombotic phenotype in mice
The gene therapy parallel is hard to miss. Just as FIX-Padua (R338L) reshaped haemophilia B gene therapy, an enhanced-potency FVIII could do the same for haemophilia A — but FVIII carries a higher VTE risk than FIX, and Aurora is a sharp reminder of how narrow the safe expression window may be.”
Title: Factor VIII Aurora: A Naturally Occurring Gain of Function FVIII Variant with Enhanced FIXa Affinity
Authors: Johnathan J. Morris, Robert J Davidson, Connor T. Watson, Lindsey A. George

Other posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Nov 13, 2026, 16:17Shailendra Singh: Bombay Hospital Jaipur Inaugurates New Facility with Voluntary Blood Donation Camp
-
Nov 13, 2026, 16:10Minka Zivkovic: UMC Utrecht Announces Research Analyst Vacancy in Thrombosis and Haemostasis
-
Nov 13, 2026, 16:02Rounak Dubey: Elsevier’s Upcoming Handbook Explores Digitalization in Transfusion Medicine
-
Nov 13, 2026, 15:50Maha Othman: CanVECTOR 2026 Highlights Research on Immunothrombosis and Cancer-Associated Thrombosis
-
Nov 13, 2026, 15:48Cedric Hermans: Advances in Gene Therapy for Haemophilia A
-
Nov 13, 2026, 15:45Strengthens Global Collaboration in Thrombosis and Hemostasis for 2027 – ISTH
-
Nov 13, 2026, 15:42David McIntosh: The Global Blood Shortage Crisis and the Urgent Need for National Action
-
Nov 13, 2026, 15:41JTH Highlights Future Directions in Thromboprophylaxis for Hospitalized Children
-
Nov 13, 2026, 15:21Wolfgang Miesbach։ Gene Therapy for Haemophilia B Is Cheaper Than Lifelong Factor IX Prophylaxis in Sweden